Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13670675 | 0.92 | MEN1 (0.51) | MEN1KMT2A | |
| SCHEMBL10509176 | 0.86 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL13742047 | 0.82 | MEN1 (0.46) | MEN1KMT2AHPGDKDM4CEP300 | |
| SCHEMBL11632204 | 0.82 | MEN1 (0.38) | MEN1KMT2AHPGDALDH1A1CYP1A2 | |
| SCHEMBL13581404 | 0.81 | MEN1 (0.46) | MEN1KMT2AHPGDKDM4CEP300 | |
| SCHEMBL6300033 | 0.81 | MAPT (0.49) | MEN1KMT2AKDM4CCYP1A2KDM4E | |
| SCHEMBL31204399 | 0.80 | MEN1 (0.47) | MEN1KMT2AKDM4CALDH1A1EP300 | |
| SCHEMBL13985724 | 0.80 | KMT2A (0.47) | MEN1KMT2AHPGDALDH1A1CYP1A2 | |
| SCHEMBL11627980 | 0.80 | MEN1 (0.42) | MEN1KMT2AKDM4CALDH1A1EP300 | |
| SCHEMBL12100411 | 0.80 | MEN1 (0.47) | MEN1KMT2AHPGDKDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | disclosed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | disclosed |
| EP-3562803-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Università degli Studi di Roma "La Sapienza" (IT) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122689-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2018-07-05 | — | — | WO | disclosed |
| WO-2008016738-A2 | ANTIBACTERIAL AGENTS AND RELATED SCREENING METHODS USING SMALL MOLECULE MACROARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-1995006628-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | MEN1 1539/4885KMT2A 910/4885HPGD 2958/4885 |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | MEN1 1539/4885KMT2A 910/4885HPGD 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.